Clinical Trial Update: Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating belimumab plus low-dose IL-2 for systemic lupus erythematosus, evaluating efficacy and immunological outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (belimumab)
• low-dose IL-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: UNKNOWN